Search clinical trials for: 흑색 종

Total 27240 results

Nanobiotix

Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Metastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditions

United States
Centre Antoine Lacassagne

Recruiting

18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma (FDG-IMMUN)

Non-Small Cell Bronchopulmonary Carcinoma or Melanoma

France
Philogen S.p.A.

Recruiting

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (NeoDREAM)

Melanoma Stage IIIB/C

Spain, United States, Switzerland
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Skin Cancer | Melanoma (Skin) | Skin Carcinoma | Skin Melanoma

United States
BioAtla, Inc.

Recruiting

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Melanoma | Head and Neck Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland
Udai Kammula

Recruiting

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

Uveal Neoplasms | Melanoma, Uveal

United States
UNC Lineberger Comprehensive Cancer Center
Pfizer; BioMed Valley Discoveries, Inc

Recruiting

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Melanoma | Pancreatic Cancer | Tumor, Solid

United States
Massive Bio, Inc.

Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Melanoma | Follicular Lymphoma | Carcinoma | Myelodysplastic Syndromes | Leukemia | Cancer | Breast Cancer | Myeloproliferative Disorders | Glioblastoma | Myelofibrosis | Ovarian Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Neuroendocrine Tumors | Non Small Cell Lung Cancer | COVID | Non Hodgkin Lymphoma | Cholang... and other conditions

United States
European Institute of Oncology
Merck Sharp & Dohme LLC

Recruiting

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Malignant Melanoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditions

United States
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Stage IV Melanoma | Stage III Melanoma

United States
Roswell Park Cancer Institute

Recruiting

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7

United States
Nantes University Hospital
Bristol-Myers Squibb

Recruiting

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients (Nivo-TIL)

Melanoma

France
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

Melanoma Stage Iv

Australia, Norway
Nantes University Hospital
Bristol-Myers Squibb; GlaxoSmithKline; Hoffmann-La Roche; Amgen; CENGEPS

Recruiting

French Clinical Datbase of Melanoma Patients (RIC-Mel) (RIC-Mel)

Melanoma (Skin)

France
Amsterdam UMC, location VUmc
Bristol-Myers Squibb

Recruiting

Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (Zirconipi)

Melanoma

Netherlands
Assistance Publique Hopitaux De Marseille

Recruiting

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Melanoma | Lung Cancer | Non-small Cell

France
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)

Head and Neck Mucosal Melanomas

France
Yana Najjar
Merck Sharp & Dohme LLC

Recruiting

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Advanced Melanoma

United States
Checkpoint Therapeutics, Inc.
Novotech (Australia) Pty Limited

Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Non Hodgkin Lymphoma | Endometrial Cancer | Carcinoma, Small Cell | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Malignant Mesothelioma, Advanced

Australia, New Zealand, Thailand, Ukraine, Spain, Russian Federation, France, Poland, South Africa
Centre Hospitalier Universitaire de Nice

Recruiting

Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma (PROTECT)

Ocular Melanoma

France
Sheba Medical Center

Recruiting

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Malignant Melanoma Stage IV

Israel
Syntrix Biosystems, Inc.
M.D. Anderson Cancer Center; National Cancer Institute (NCI); Massachusetts General... and other collaborators

Recruiting

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Melanoma Stage IV | Melanoma Stage III

United States
Uppsala University

Recruiting

A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma (TRIM)

Malignant Melanoma

Sweden
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

Spain, Japan, Korea, Republic of, Taiwan, Netherlands, United States, Italy, Canada, Singapore
M.D. Anderson Cancer Center
Gateway for Cancer Research; James B. and Lois R. Archer Charitable Foundation

Recruiting

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Melanoma and Other Malignant Neoplasms of Skin | Malignant Neoplasm of Bone and Articular Cartilage | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasm of Male... and other conditions

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Recruiting

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Brain Metastases

United States
St. Jude Children's Research Hospital

Recruiting

Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)

Pancreatic Cancer | Hodgkin Lymphoma | Lynch Syndrome | Tuberous Sclerosis | Fanconi Anemia | AML | Non Hodgkin Lymphoma | Familial Adenomatous Polyposis | Acute Leukemia | Nevoid Basal Cell Carcinoma Syndrome | Neurofibromatosis Type 1 | Neuroblastoma | Retinoblastoma | MDS | Rhabdomyosarcoma | Von Hippel-Lindau Disease | Adrenocortical Carcinoma and other conditions

United States
Inge Marie Svane

Recruiting

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Metastatic Melanoma

Denmark
Chung Mei Biopharma Co., Ltd

Not yet recruiting

Safety and Efficacy of DCB-BO1301 in Advanced Melanoma

Advanced Melanoma
Radboud University Medical Center
The Netherlands Cancer Institute; Isala

Recruiting

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (COWBOY)

Melanoma, Malignant, of Soft Parts

Netherlands
Philogen S.p.A.

Recruiting

Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal)

Malignant Melanoma

Italy, France, Germany, Poland
Charite University, Berlin, Germany

Recruiting

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis (SirTac)

Uveal Melanoma

Germany
Amgen

Recruiting

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Melanoma | Herpetic Infection

United Kingdom, Austria, United States, Israel, Switzerland
Universitair Ziekenhuis Brussel

Recruiting

Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. (DW-MRi)

Melanoma

Belgium
University Health Network, Toronto
Princess Margaret Hospital, Canada

Recruiting

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE)

Melanoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Unknown Primary Cancer | Gynecological Cancer | Rare Cancer | Pancreatobiliary Cancer

Canada
Institut Claudius Regaud

Recruiting

Prospective Melanoma Database

Melanoma

France
Loyola University
National Cancer Institute (NCI)

Recruiting

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Melanoma

United States
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI)

Recruiting

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary (MelBase)

Malignant Melanoma

France
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Tesaro, Inc.

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
Massachusetts General Hospital
Dana-Farber Cancer Institute

Recruiting

GI Complications in Cancer Immunotherapy Patients

Malignant Melanoma

United States
St. Jude Children's Research Hospital

Recruiting

Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

Melanoma

United States
Yale University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer

Melanoma | Non-small Cell Lung Cancer | Brain Metastasis

United States
Universitair Ziekenhuis Brussel

Recruiting

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma (ICIT)

Malignant Melanoma

Belgium
Melanoma Institute Australia
Novartis

Recruiting

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

Melanoma

Australia
Yonsei University

Recruiting

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Melanoma

Korea, Republic of

Search clinical trials for: 흑색 종

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations